17.01.2023 22:14:22
|
Moderna RSV Vaccine Meets Primary Endpoints In Phase 3 Trial
(RTTNews) - Moderna, Inc. (MRNA), Tuesday announced positive topline data from its Phase 3 efficacy trial of mRNA-1345, an investigational mRNA vaccine targeting respiratory syncytial virus in older adults.
Following review by an independent Data and Safety Monitoring Board, the primary efficacy endpoints have been met, including vaccine efficacy of 83.7% against RSV-associated lower respiratory tract disease as defined by two or more symptoms.
Moderna said it intends to submit for regulatory approval in the first half of 2023.
"Today's results represent an important step forward in preventing lower respiratory disease due to RSV in adults 60 years of age and older. These data are encouraging, and represent the second demonstration of positive phase 3 trial results from our mRNA infectious disease vaccine platform after, Spikevax, our COVID-19 vaccine. We look forward to publishing the full data set and sharing the results at an upcoming infectious disease medical conference," said Stéphane Bancel, Moderna's Chief Executive Officer.
"Respiratory diseases are a major public health priority given they have a significant health impact and are a leading cause of hospitalization. For these reasons, in addition to our mRNA-1345 RSV vaccine candidate, we are committed to developing a portfolio of respiratory mRNA vaccines to target the most significant viruses causing respiratory disease, including COVID-19, influenza, and human metapneumovirus."
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Moderna Incmehr Nachrichten
20.12.24 |
Freitagshandel in New York: NASDAQ 100 zum Start des Freitagshandels schwächer (finanzen.at) | |
19.12.24 |
Donnerstagshandel in New York: NASDAQ 100 zum Ende des Donnerstagshandels in der Verlustzone (finanzen.at) | |
19.12.24 |
S&P 500-Titel Moderna-Aktie: So viel hätten Anleger an einem Moderna-Investment von vor einem Jahr verloren (finanzen.at) | |
19.12.24 |
Starker Wochentag in New York: NASDAQ 100-Börsianer greifen zum Handelsstart zu (finanzen.at) | |
18.12.24 |
Pluszeichen in New York: S&P 500 startet in der Gewinnzone (finanzen.at) | |
18.12.24 |
Schwacher Wochentag in New York: NASDAQ 100 liegt zum Start im Minus (finanzen.at) | |
16.12.24 |
Börse New York: Zum Start des Montagshandels Gewinne im NASDAQ 100 (finanzen.at) | |
16.12.24 |
Börse New York: S&P 500-Börsianer greifen zum Start des Montagshandels zu (finanzen.at) |
Analysen zu Moderna Incmehr Analysen
19.11.24 | Moderna Hold | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
13.09.24 | Moderna Underweight | JP Morgan Chase & Co. | |
05.08.24 | Moderna Sector Perform | RBC Capital Markets | |
12.01.24 | Moderna Outperform | RBC Capital Markets | |
03.11.23 | Moderna Buy | Goldman Sachs Group Inc. |